ArticleBMC neurology2025
Anti-dipeptidyl-peptidase-like protein-6 antibody-associated encephalitis masquerading as weight loss and confusion: a case report.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-Dipeptidyl-peptidase-like protein-6 (DPPX) antibody-associated encephalitis is a rare autoimmune condition that affects the central and enteric nervous systems. It often presents with neuropsychiatric symptoms, cerebellar ataxia, and gastrointestinal dysmotility, though clinical manifestations can vary widely. CASE PRESENTATION: We report the case of a 38-year-old woman with psychiatric symptoms who developed severe cognitive impairment, seizures, and a profound weight loss of 100 pounds over one year. Her symptoms initially led to multiple psychiatric diagnoses and treatments, delaying recognition of the underlying autoimmune process. Ultimately, cerebrospinal fluid analysis revealed high-titer anti-DPPX antibodies (1:1000). Despite aggressive immunotherapy—including corticosteroids, plasmapheresis, IVIG, and rituximab—the patient’s condition deteriorated, and she died under hospice care. DISCUSSION: This case expands the known clinical spectrum of anti-DPPX encephalitis by documenting the most extreme reported case of weight loss associated with the disease. The prodromal presentation with isolated weight loss underscores the diagnostic challenges when neuropsychiatric symptoms emerge late. Our case highlights the importance of maintaining clinical suspicion for autoimmune encephalitis in patients with unexplained weight loss and neurocognitive decline.
conclusionProfound, unexplained weight loss may be an early and under-recognized manifestation of anti-DPPX encephalitis. Early recognition and immunotherapy are critical, but the potential for rapid progression and relapse demands heightened clinical vigilance and further research into optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.